For patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions

CREON Brings Nutrient
Absorption to the Table1

Learn More About CREON
CREON® (pancrelipase) dosing range and chart two CREON 1236, 36K dose capsules

Getting started with

36K capsules can be an appropriate strength for
many patients1

See CREON dosing overview

CREON 36,000 may not be appropriate for all patients. CREON is available in 3,000,
6,000, 12,000, and 24,000 lipase unit capsules.1
Capsules shown are not actual size and do not represent exact color shade. For illustrative purposes only. The active ingredient in CREON evaluated in clinical trials is lipase.
Example per-meal starting dose for a patient who weighs ≥160 lb to 315 lb.1

Patient Support Programs

Most eligible CREON patients could PAY $5 (or less) per month regardless of prescription cost2*

Source: Amundsen Group, Jan 2016–Sept 2017, 2017.

View complete
program details
Eligible CREON patients PAY $0 when commercial prescription cost is $100 or less, or as little as $5 when prescription cost is $105 or more

*Eligibility: Available to patients with commercial prescription insurance coverage for CREON who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare program, patient will no longer be able to use the Co-Pay card and patient must call 1-855-CARE4WD (227-3493) if enrolled in CFCareForward or 1-844-ONCREON (662-7366) if enrolled in CREON On Course to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the CFCareForward or CREON On Course from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. Please see full Terms and Conditions.

Starting Your Patients on CREON

Dr. Mehdizadeh offers helpful tips for getting patients off to a good start on CREON therapy.

Video Transcript

Narrator: Dr. Mehdizadeh

I’m Dr. Shahab Mehdizadeh and I’m board certified in gastroenterology, internal medicine, and in nutrition.

I consider a few key things when I’m putting together a treatment plan for a patient with EPI due to chronic pancreatitis, pancreatectomy, or other conditions.

First, it typically includes pancreatic enzyme replacement therapy.

Second, I will talk about diet and discuss if dietary modifications may be needed.

Third, I also will recommend lifestyle modifications. I emphasize the importance of abstinence from smoking and alcohol as these can further damage the pancreas.

It is really important to educate patients when starting any therapy.

I think it is key for my patients to understand why I’m prescribing enzymes to them.

Taking CREON, which is a pancreatic enzyme replacement therapy, with meals and snacks...can help improve the digestion of fat, proteins, and sugars from food.

Exercise caution when administrating pancrelipase to a patient with a known allergy to proteins of porcine origin.

I want to make sure the dose I prescribe is working for them, so I explain that the CREON dose that I’m prescribing is a starting point. I ask my patients to track their diet and how they are feeling and emphasize to them the importance of this information.

When taking Creon, it’s important to follow the dosing instructions provided by your healthcare professional.

I will use this information to see if any adjustments are needed to their CREON starting dose when they return for a follow-up visit.

A diet journal can really be helpful for getting patients to think about what they’re eating.

I remind my patients that CREON should be taken with every meal and snack.

I tell my patients who are newly starting out to just put the capsules right there on the side of their plate so they don’t forget.

I’ll also tell them to set reminders on their phone, anything that will help them get in the habit.

It is important not to crush or chew CREON capsules or its contents and not to hold capsules in their mouth.

Crushing, chewing, or holding the CREON capsules in the mouth may cause irritation in the mouth.

I encourage my eligible patients to enroll in one of the patient support programs offered on

For patients with EPI due to cystic fibrosis, CREON offers the CFCareForward program, and for patients with EPI due to other conditions including chronic pancreatitis and pancreatectomy, there is the CREON On Course program.

Contact a CREON
Sales Representative

If you are a healthcare provider and would like CREON co-pay cards, product samples, patient educational materials, and more, please click below.

Request Information

Indications and Important
Safety Information


CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. References:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.
  3. Data on file. North Chicago, IL: AbbVie Inc. Source: Amundsen Group, Jan 2016‑Sept 2017, 2017.

back to top #tbd